Why Is KRYSTAL BIOTECH INC (KRYS) Stock Down Today?
By the Top Tier Newswire AI Desk · August 4, 2026 at 12:09 AM ET · reviewed against 8 wire stories
KRYSTAL BIOTECH INC (KRYS) is down -8.37% in the latest session. Our newswire has captured 8 stories on KRYS across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 53/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
KRYS stock fell 8.37% to $312.57 in the session, driven by mixed second-quarter results and investor reaction to guidance. While Krystal Biotech reported GAAP earnings per share of $1.79, which beat estimates by $0.16, revenue of $119.22 million came in $1.82 million below forecasts. The company also outlined a 2026 non-GAAP operating expense range of $175 million to $195 million, and investors appeared to weigh the revenue shortfall and evolving financial commitments.
What Happened
Krystal Biotech reported second-quarter 2026 results on August 3, 2026, with GAAP EPS of $1.79, exceeding the expected $1.63. However, revenue of $119.22 million, while up 24% year over year, fell short of the $121.06 million forecast. The company attributed the revenue miss to timing of VYJUVEK sales and the impact of Germany pricing accruals. Despite robust global VYJUVEK revenue of $119.2 million for the quarter and $965.9 million since launch, the stock declined on concerns over near-term revenue visibility and the outlined expense guidance. The firm also announced it is advancing KB801 into a pivotal trial after discontinuing a clinical study with no safety concerns observed.
What The Data Shows
Krystal Biotech ended the quarter with $1.1 billion in cash and a net margin of 53.9%. The stock has traded between $130.50 and $382.54 over the past 52 weeks. Recent insider transactions include four sales totaling $15.9 million in the last 90 days, with the most recent filing on June 26. Additionally, Donald J. Trump sold between $15,001 and $50,000 in the stock on May 15. The stock’s beta of 0.50 suggests it is less volatile than the broader market, but the sharp intraday move reflects immediate investor reaction to the earnings report and guidance.
What To Watch
The company has no upcoming earnings reports in the near term. Investors should monitor coverage breadth and analyst commentary, particularly as B of A Securities and TD Cowen have both raised price targets to $396 and $403 respectively, maintaining Buy ratings.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
KRYS · Aug 4 session (5-min) · +3.90% vs prior close · updated 8:55 PM ETAI sentiment, last 36h · averaged over 8 stories · 53/100 neutral
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
7d agoSeeking AlphaBULLISH 56General
Krystal Biotech outlines $175M-$195M 2026 non-GAAP opex range as VYJUVEK expands overseas pricing talks
Krystal Biotech (KRYS) Q2 2026 earnings call: VYJUVEK revenue, Germany pricing accrual impact, Europe launch progress, and 2026-27 catalyst timeline—read...
7d agoSeeking AlphaNEUTRAL 50Earnings
Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript
Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call August 3, 2026 8:30 AM EDTCompany ParticipantsStephane Paquette - Senior Vice President of Corporate...
Krystal Biotech beat second-quarter earnings estimates but missed revenue forecasts as VYJUVEK sales continued to grow and the company expanded its commercial presence across Europe.
7d agoMarketChameleonBULLISH 73Earnings
Krystal Biotech’s Q2 2026: Robust VYJUVEK Momentum, Multiple Late-Stage Readouts Ahead, and Strong Financials
August 3, 2026
Krystal Biotech delivered $119.2 million in global VYJUVEK revenue in Q2 2026 and ended the quarter with $1.1 billion in cash. With several pivotal clinical readouts, international launches, and a growing pipeline in the next year, KRYS is aiming for a transition from a single-product leader to a multi-product genetic medicine company.
7d agoInvesting.com MarketsBEARISH 34General
Why is Krystal Biotech stock sliding today?
Why is Krystal Biotech stock sliding today?
7d agoSeeking AlphaBULLISH 56Earnings
Krystal Biotech GAAP EPS of $1.79 beats by $0.16, revenue of $119.22M misses by $1.82M
Krystal Biotech (KRYS) Q2 results: GAAP EPS beats, revenue up 24% Y/Y but misses; VYJUVEK sales and FY2026 expense guidance.
7d agoSEC 8-KNEUTRAL 50General
Krystal Biotech, Inc. (KRYS) files 8-K
Filed: 2026-08-03 AccNo: 0001711279-26-000058 Size: 587 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
7d agoBusiness InsiderBULLISH 63Earnings
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →